drugset
Drugs / CFTX-1554
last change Apr 2026 re-read 3 minutes ago

CFTX-1554

Investigated by
Confo Therapeutics

Trials 1

today NCT05260658 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05260658 Feb 2022 → Feb 2023 — Confo Therapeutics Completed No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2026-04-30 Confo Therapeutics Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554 confotherapeutics.com ↗
2023-03-02 Confo Therapeutics Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554 confotherapeutics.com ↗
2022-09-15 Confo Therapeutics Confo Therapeutics Announces Poster Presentations on CFTX-1554 Preclinical Profiling and Mechanism of Action at the IASP 2022 World Congress on Pain confotherapeutics.com ↗
2022-03-10 Confo Therapeutics Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain confotherapeutics.com ↗
2021-03-30 Confo Therapeutics Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain confotherapeutics.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CFTX-1554 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05260658 ↗
Route Oral “Single and Multiple Ascending Oral Doses of CFTX-1554” NCT05260658 ↗